Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH. The launch of Olanzapine for Injection underscores its strategic focus on growing a robust injectables portfolio and strengthening its presence within the institutional channel.
According to IQVIA sales data for the 12-month period ending May 2026, the Zyprexa IntraMuscular Injection market achieved annual sales of around $25.4 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
